Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients. The company expects the new pediatric presentations to become available in October. The supporting pediatric study was open-label and assessed treatment over 12 weeks, reporting reductions in lymph-node size and improvements in immune-cell measures. Reported
0